Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, golimumab (Simponi®) cannot be endorsed for use within NHS Wales in combination with methotrexate for the treatment of polyarticular juvenile idiopathic arthritis in children with a body weight of at least 40 kg, who have responded inadequately to previous therapy with methotrexate. |
||
|
||
Medicine details |
||
| Medicine name | golimumab (Simponi®) | |
| Formulation | 50 mg solution for injection | |
| Reference number | 1324 | |
| Indication | In combination with methotrexate for the treatment of polyarticular juvenile idiopathic arthritis in children with a body weight of at least 40 kg, who have responded inadequately to previous therapy with methotrexate. |
|
| Company | Merck Sharp & Dohme Ltd | |
| BNF chapter | Musculoskeletal & joint diseases | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 29/09/2016 | |